90921-10-1 Usage
Description
4-oxo-3,4-dihydro-2H-chromene-8-carboxylic acid is an organic compound that serves as a key intermediate in the synthesis of various pharmaceutical compounds. It is characterized by its unique structure, which includes a chromene ring fused with a dihydro ring and a carboxylic acid group. 4-oxo-3,4-dihydro-2H-chroMene-8-carboxylic acid has potential applications in the development of new drugs with therapeutic benefits.
Uses
Used in Pharmaceutical Industry:
4-oxo-3,4-dihydro-2H-chromene-8-carboxylic acid is used as a key intermediate in the synthesis of new 4-benzopyranone derivatives. These derivatives exhibit analgesic, anti-inflammatory, and platelet anti-aggregating activities, making them valuable for the development of medications to treat pain, inflammation, and blood clotting disorders.
In the synthesis of these 4-benzopyranone derivatives, 4-oxo-3,4-dihydro-2H-chromene-8-carboxylic acid plays a crucial role in providing the necessary structural framework for the development of these therapeutic agents. Its versatility in chemical reactions allows for the creation of a wide range of compounds with diverse pharmacological properties, contributing to the advancement of medicine and healthcare.
Check Digit Verification of cas no
The CAS Registry Mumber 90921-10-1 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 9,0,9,2 and 1 respectively; the second part has 2 digits, 1 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 90921-10:
(7*9)+(6*0)+(5*9)+(4*2)+(3*1)+(2*1)+(1*0)=121
121 % 10 = 1
So 90921-10-1 is a valid CAS Registry Number.
90921-10-1Relevant articles and documents
SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME
-
Page/Page column 66, (2018/04/14)
The present invention includes novel substituted bicyclic (such as 4-substituted-chromane-8-carboxamide compounds), and compositions comprising the same, that can be used to treat or prevent hepatitis B virus (HBV) infections in a patient. In certain embodiments, the compounds and compositions of the invention are capsid inhibitors.
